Book Navigation
 

International guideline library update

New in the International Guideline Library – 2 April to 25 June 2012

Organisation

ACP (US)

Screening for Colorectal Cancer: A Guidance Statement From the American College of Physicians

AHRQ (US)

Practice guidelines for central venous access. A report by the American Society of Anesthesiologists Task Force on Central Venous Access. American Society of Anesthesiologists.

AHRQ (US)

Practice advisory for preanesthesia evaluation. An updated report by the American Society of Anesthesiologists Task Force on Preanesthesia Evaluation. American Society of Anesthesiologists.

AHRQ (US)

Management of gynecologic issues in women with breast cancer. American College of Obstetricians and Gynecologists.

ASCO (US)

Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline

AUA (US)

Diagnosis, Evaluation and Follow-Up of Asymptomatic Microhematuria (AMH) in Adults: AUA Guideline

AUA (US)

Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline (2012)

AUA (US)

Vasectomy: AUA Guideline (2012)

AUA (US)

American Urological Association (AUA)/Society Of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Guideline (2012)

AWMF (DE)

Lokaltherapie chronischer Wunden bei Patienten mit den Risiken periphere arterielle Verschlusskrankheit, Diabetes Mellitus, chronisch venöse Insuffizienz. S3-LL (DGfW, DDG, DDG)
[Management of chronic wounds in patients with the risk of arterial occlusive disease, diabetes mellitus, chronic venous insufficiency]

AWMF (DE)

Bisphosphonat-assoziierte Kiefernekrosen. S3-LL (DGMKG, DGE, DGGG)
[Prophylaxis and management of biophosphate-associated jaw necrosis]

AWMF (DE)

Umgang mit Patienten mit nicht-spezifischen, funktionellen und somatoformen Körperbeschwerden. S3-LL (DGPM, DKPM, DDG)
[Somatoform disorders]

AWMF (DE)

Diagnostik und Therapie der Multiplen Sklerose. S2e-LL (DGN, BVDN, BDN)
[Diagnosis and treatment of multiple sclerosis]

AWMF (DE)

Rektovaginale Fistel. S3-LL (DGAV, DDG, DGGG)
[Rectovaginal fistula]

AWMF (DE)

Fibromyalgiesyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. S3-LL (DIVS/DEGAM/DGN)
[Diagnosis and management of fibromyalgia]

AWMF (DE)

Zahnärztlich-chirurgische Sanierung vor Herzklappenersatz. S2k-LL (DGMKG/DGZMK)
[Dental surgery prior to heart valve replacement]

HAS (FR)

Label INCa-Has - Surveillance médico-professionelle des travailleurs exposés ou ayant été exposé à des agents cancérogènes chimiques: application aux cancérogènes pour la vessie. Recommandation pour la pratique clinique

IQWiG (DE)

Vandetanib - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Vandetanib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

IQWiG (DE)

Vemurafenib - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Vemurafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

IQWiG (DE)

Ipilimumab - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Ipilimumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

IQWiG (DE)

Belimumab - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Belimumab - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)]

IQWiG (DE)

Fampridin - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Fampridine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

IQWiG (DE)

Emtricitabin/Rilpivirin/Tenofovirdisoproxil - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Emtricitabine/rilpivirine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

IQWiG (DE)

Belatacept - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Belatacept -Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

IQWiG (DE)

Rilpivirin - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Rilpivirine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

IQWiG (DE)

Extrakt aus Cannabis Sativa: Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Extract from Cannabis sativa L. - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

IQWiG (DE)

Positronen-Emissions-Tomographie (PET) bei Ovarialkarzinom
[Positron emission tomography (PET) in ovarian cancer]

MoH (UA)

Артеріальна гіпертензія. Оновлена та адаптована клінічна настанова, заснована на доказах
[Hypertension. Updated and adapted evidence-based guideline]

MoH (UA)

Контроль болю. Адаптована клінічна настанова, заснована на доказах
[Pain control. Adapted evidence-based guideline]

NICE (GB)

Acute upper GI bleeding

NICE (GB)

Opioids in palliative care (CG140)

SIGN (GB)

The SIGN discharge document (SIGN CPG 128)

SIGN (GB)

Management of perinatal mood disorders (SIGN CPG 127)

 
enGINe Newsletter

Subscribe here to the enGINe Newsletter.


Page last updated: Jul 03, 2012
Copyright © 2002-2016 Guidelines International Network.
All rights reserved

The Guidelines International Network is formally constituted as a Scottish Guarantee Company under Company Number SC243691 and recognised as a Scottish Charity under Scottish Charity Number SC034047 with its Registered Office at J. & H. Mitchell W.S., 51 Atholl Road, Pitlochry, Perthshire PH16 5BU, Scotland.

Back to top